A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor α biological treatments according to the current guidelines
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor α biological treatments according to the current guidelines
复制标题
根据现行指南，在三级临床护理中随访的大部分强直性脊柱炎患者需要抗肿瘤坏死因子 α 生物治疗
DOI：
--
复制
发表时间：
2005
影响因子：
27.4
通讯作者：
Hans
中科院分区：
文献类型：
--
作者：
T. Bihl;E. Vassina;M. K. Boettger;R. Goldbach;Michael Seitz;P. M. Villiger;Hans
严重强直性脊柱炎 (AS) 的治疗选择仅限于非甾体类抗炎药 (NSAID)、皮质类固醇和一些传统的疾病缓解药物 (DMARD)，例如柳氮磺吡啶和甲氨蝶呤。鉴于单克隆嵌合肿瘤坏死因子 (TNF) α 抗体（英夫利昔单抗）和重组人 TNF 受体（依那西普）治疗的开放标签和对照试验，似乎满足了对 AS 更有效二线治疗的需求。 1-4
在这项研究中，我们的目的是使用三级临床护理中抗 TNF 治疗的现行指南，确定尽管接受非甾体抗炎药和二线治疗（柳氮磺吡啶、甲氨蝶呤）治疗的活动性 AS 患者的比例。
研究患者是根据改良纽约标准选择的。 ASAS 和 SPARTAN 的 AS 生物治疗指南……
Therapeutic options for severe ankylosing spondylitis (AS) have been limited to non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and to some traditional disease modifying drugs (DMARDs) such as sulfasalazine and methotrexate. In view of open label and controlled trials of treatment with a monoclonal chimeric tumour necrosis factor (TNF) α antibody (infliximab), and with recombinant human TNF receptor (etanercept), the need for more effective second line treatments in AS seems to be met.1–4
In this study we aimed at determining the proportion of patients with active AS, despite treatment with NSAIDs and second line treatments (sulfasalazine, methotrexate), using current guidelines for anti-TNF treatment in a tertiary clinical care.
Study patients were selected according to the Modified New York criteria. ASAS and SPARTAN guidelines for biological treatments of AS were …
DOI：
--
发表时间：
2003
期刊：
--
影响因子：
--
作者：
S. Rybalkin;C. Yan;K. Bornfeldt;J. Beavo
通讯作者：
S. Rybalkin;C. Yan;K. Bornfeldt;J. Beavo
家族性地中海热患者常见基因型的基因型-表型评估。
DOI：
--
发表时间：
2000
期刊：
The Journal of rheumatology
影响因子：
--
作者：
Shinar,Y;Livneh,A;Langevitz,P;Zaks,N;Aksentijevich,I;Koziol,DE;Kastner,DL;Pras,M;Pras,E
通讯作者：
Pras,E
影响因子：
--
作者：
Aksentijevich, I;Nowak, M;Goldbach-Mansky, R
通讯作者：
Goldbach-Mansky, R